Comparison between linear and star-like HPMA conjugated pirarubicin (THP) in pharmacokinetics and antitumor activity in tumor bearing mice

Eur J Pharm Biopharm. 2015 Feb:90:90-6. doi: 10.1016/j.ejpb.2014.10.007. Epub 2014 Nov 8.

Abstract

Previously we showed that linear poly(N-(2-hydroxypropyl)methacrylamide) conjugates of pirarubicin (THP), LP-THP, with MW about 39 kDa, exhibited far better tumor accumulation and therapeutic effect than that of parental free THP. To improve the pharmacokinetics of LP-THP further, high-MW conjugate of poly(amido amine) (PAMAM) dendrimer grafted with semitelechelic HPMA copolymer (PHPMA) was synthesized [star polymer (SP); 400 kDa] and conjugated with THP via hydrazone bond-containing spacer (SP-THP). THP was conjugated to SP to form SP-THP via acid cleavable hydrazone bonding, which responds to acidic milieu of tumor tissue. As a consequence, it would release free THP, by active therapeutic principle. SP-THP exhibits larger hydrodynamic diameter (25.9 nm) in aqueous solution than that of LP-THP (8.2 nm) as observed by light scattering and size exclusion chromatography. Because of the larger size, the tumor AUC5h-72 h of SP-THP was 3.3 times higher than that of LP-THP. More importantly, released free THP was retained selectively in the tumor tissue for at least up to 72 h after administration of SP-THP. We found that SP-THP exhibited superior antitumor effect to LP-THP against both S-180 tumor-bearing mice in vivo, and with chemically AOM/DSS-induced colon tumor-bearing mice, most probably due to their different molecular size. In our comparison study of in vitro and in vivo behavior of SP-THP and LP-THP we concluded that SP-THP exhibited enhanced therapeutic efficacy not only in implanted tumor but also in orthotopic/spontaneous tumor despite its higher toxicity compared to LP-THP. Upon these findings further investigation using various tumors including transgenic, and metastatic tumors is going to be conducted soon.

Keywords: Acid-cleavable linkage; Chemical carcinogenesis; Controlled drug release; Dendrimer-derived polymer conjugate; EPR effect; HPMA polymer conjugate; Pirarubicin (THP).

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antineoplastic Agents / chemistry
  • Antineoplastic Agents / pharmacokinetics*
  • Antineoplastic Agents / pharmacology*
  • Berberine Alkaloids / chemistry*
  • Berberine Alkaloids / pharmacokinetics
  • Cell Line, Tumor
  • Dendrimers / chemistry
  • Dendrimers / pharmacokinetics
  • Doxorubicin / analogs & derivatives*
  • Doxorubicin / chemistry
  • Doxorubicin / pharmacokinetics
  • Doxorubicin / pharmacology
  • Drug Carriers / chemistry
  • Drug Carriers / pharmacokinetics
  • HeLa Cells
  • Humans
  • Male
  • Melanoma, Experimental
  • Methacrylates / chemistry*
  • Methacrylates / pharmacokinetics
  • Mice
  • Mice, Inbred ICR
  • Neoplasms / drug therapy*
  • Polymers / chemistry
  • Polymers / pharmacokinetics

Substances

  • 2,3,10,11-tetrahydroxytetrahydroprotoberberine
  • Antineoplastic Agents
  • Berberine Alkaloids
  • Dendrimers
  • Drug Carriers
  • Methacrylates
  • PAMAM Starburst
  • Polymers
  • Doxorubicin
  • pirarubicin
  • hydroxypropyl methacrylate